Cutiss

CUTISS is a pioneering Swiss biotech company developing denovoSkin™, a personalized, bioengineered skin graft intended to replace the current standard of autografting. The company operates a state-of-the-art GMP facility and has developed a proprietary, automated manufacturing platform for scalable production. With denovoSkin™ in late-stage clinical trials and holding Orphan Drug Designations from major regulatory bodies, CUTISS is positioned to address significant unmet needs in burn care, reconstructive surgery, and beyond, while also exploring applications in regenerative medicine and space health research.

Proprietary, automated, closed-system platform for scalable bio-manufacturing of personalized tissue grafts (denovoSkin™). Also holds license for Viticell®, a cell therapy device for skin pigmentation restoration.

CUTISS is first-in-class with a personalized, bioengineered skin graft. It competes against the entrenched standard of care (autografting) and a range of wound care products, skin substitutes, and scaffolds that support or augment autografting. Its fully integrated, automated production platform for a living bilayer skin graft is a key differentiator from other tissue engineering approaches.